Scientist, Targeted Delivery

Overview

The Research Department at Alnylam is seeking a Scientist to join a growing team responsible for advancing RNAi therapeutics into the future, by opening up targeted delivery to all tissues. The successful candidate will have a working knowledge of receptor biology and ligand/receptor characterization. Proficiency in AAV capsid engineering, in vivo phage display, and/or receptor deconvolution is highly desired. This role requires hands-on expertise in tools and techniques used to identify receptors and characterize ligand-receptor interactions. The individual will need excellent collaboration and communication skills to work collaboratively across the research department.

This position is lab-based onsite and will be primarily located in Cambridge, MA.  

Key Responsibilities

• Contribute to an interdisciplinary team focused on expanding targeted delivery into new cell types and tissues.
• Establish tools, techniques, and assays to identify and characterize new receptors to unlock targeted delivery into new cell types and tissues.
• Transparently communicate results with key stakeholders throughout the organization.

Qualifications

• PhD in Biochemistry, Molecular Biology, Cell Biology, or related field.
• 0-3 years of experience in biopharma setting.
• Expertise in receptor biology and characterizing ligand/receptor interactions
• Strong background in protein chemistry and binding assays including ELISA, Western blot, and BLI/SPR.
• Experience with unbiased approaches for novel ligand/receptor discovery including in vivo phage display, AAV capsid engineering, and/or receptor deconvolution (e.g. protein microarray, protein cross linking for mass spec analysis, etc.)
• Excellent communication skills (both written and oral) are essential.

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.